Historical Stock Chart
From Jun 2019 to Jun 2020
Beovu showed it was non-inferior in terms of improvements in visual acuity for patients compared with rival treatment aflibercept. "Novartis Sees Blockbuster Potential in Eye-Disease Drug -- Update," on Oct. 8 at GMT 1216, misstated that Beovu achieved superior visual improvements compared with aflibercept in the fifth paragraph. The error also appeared in an earlier version of the story, "Novartis: US FDA Approves Eye-Disease Treatment Beovu," at 0535 GMT the same day.
(END) Dow Jones Newswires
October 09, 2019 13:23 ET (17:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.